CN103735564A - Medicinal composition for preventing fatty liver and application thereof - Google Patents
Medicinal composition for preventing fatty liver and application thereof Download PDFInfo
- Publication number
- CN103735564A CN103735564A CN201410033079.8A CN201410033079A CN103735564A CN 103735564 A CN103735564 A CN 103735564A CN 201410033079 A CN201410033079 A CN 201410033079A CN 103735564 A CN103735564 A CN 103735564A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- fatty liver
- friedelan
- group
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and in particular relates to a medicinal composition for preventing fatty liver and application thereof. The medicinal composition is prepared from the following raw materials: friedelan-3 beta-ol, astragalus polysaccharide component A1, resveratrol and ajugol A. The medicinal composition can be used for effectively preventing fatty liver, has the advantages of remarkable treatment effect and stable quality control, and is suitable for long time administration of patients.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of pharmaceutical composition and application thereof that prevents fatty liver.
Background technology
Fatty liver refers to because of intrahepatic fat oxidation reduction, and fatty acid is synthetic to be increased, the comprehensive metabolic disease of one in hepatocyte due to athero.
The definite pathogeny of fatty liver is not yet clear and definite, and the imbalance of body lipid metabolism is the key factor of bringing out fatty liver.Clinically, Patients with Fatty Liver often serum total cholesterol and triglyceride obviously raises, and high density lipoprotein obviously declines.Therefore, the mensuration of serum total cholesterol (TC), triglyceride (TG) and HDL-C (HDL-C) can be used as the efficiency index that detects fatty liver.Simultaneously, when liver cell is impaired, alanine aminotransferase (ALT) and aspartate transaminase (AST) overflow and cause Serum ALT and AST content to raise, so can reflect degree and the hepatocellular reparation situation of Patients with Fatty Liver hepatocellular damage by measuring Serum ALT and AST activity.
At present, the common drug for the treatment of fatty liver comprises: 1. Chinese medicine class is as Rhizoma Curcumae Longae, Radix Polygoni Multiflori Preparata, Fructus Crataegi etc., and Main Function is blood fat reducing, prevents that cholesterol is at intrahepatic deposition; 2. Western medicine class is as vitamin B, C, E, lecithin, ursodesoxycholic acid, silymarin, inosine, coenzyme A, reduced glutathion, taurine, carnitine Orotate etc., and Main Function is protection hepatocyte, increase fat transfer function and antioxidant.
Summary of the invention
The object of the invention is to overcome defect of the prior art, and provide a special quality control stable, safe and effective, Nantural non-toxic and and be suitable for pharmaceutical composition and the application thereof of the prevention fatty liver of long-term taking.
The object of the present invention is achieved like this: it is formulated that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol, astragalus polysaccharides component A1, resveratrol and Herba Leonuri glycosides A.
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol 1-100 part, astragalus polysaccharides component A13-100 part, resveratrol 5-100 part and Herba Leonuri glycosides A1-100 part.
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol 1-80 part, astragalus polysaccharides component A13-80 part, resveratrol 5-80 part and Herba Leonuri glycosides A1-80 part.
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol 1-50 part, astragalus polysaccharides component A13-50 part, resveratrol 5-50 part and Herba Leonuri glycosides A1-50 part.
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 1 part of friedelan 3 βol, astragalus polysaccharides component A13 part, 5 parts of resveratrols and Herba Leonuri glycosides A1 part.
The invention provides the application of aforementioned pharmaceutical compositions in the medicine of preparation prevention fatty liver.
Friedelan 3 βol of the present invention, astragalus polysaccharides component A1, resveratrol and Herba Leonuri glycosides A can directly obtain by commercially available, also can obtain by plant extract.
The present invention pulverizes and sieves above-mentioned raw materials respectively by weight, mixes, and incapsulates or be compressed to tablet; Or with pharmaceutically acceptable carrier or mixing diluents, reinstall capsule or be compressed to tablet.
The present invention also provides the instructions of taking of described pharmaceutical composition, and its dose is in said composition: adult, 10～15mg/ time, 3 times/day; Child, 3～5mg/kg time, 3 times/day, can reach the effect of preventing fatty liver clinical symptoms, particularly point out, when taking, the special populations such as anemia of pregnant woman need follow the doctor's advice, not yet find at present its special untoward reaction.Prevention of the present invention means premorbid intervention, does not represent the treatment after morbidity.
Friedelan 3 βol in the present invention, is extracted from the leaf of Celastraceae plant winged euonymus [Euonymus alatus (Thunb.) Sieb.] and Euonymus japonicus [Euonymus japonicus Thunb.]; Feverfew Herba Lycopi's [Eupatorium japonicum Thunb.] leaf, stem; Euphorbia plant Buddha's warrior attendant is stem, the leaf of [Euphorbia antiquorum L.] and Bischofia javanica Bl [Bischofia polycarpa (Levl.) Airy Shaw] very.Molecular formula: C
30h
52o, molecular weight: 428.73.
Astragalus polysaccharides component A1, is extracted from the rhizome of the leguminous plant Radix Astragali [Astragalus membranceus (Ficch.) Bunge.].
Resveratrol, is extracted from fresh of polygonaceae plant Rhizoma Polygoni Cuspidati [Polygonum cuspidatum Sieb.et Zucc].Molecular formula: C
14h
12o
3, molecular weight: 228.24.
Herba Leonuri glycosides A, is extracted from the young stem and leaf of labiate Herba Leonuri [Leonurus japonicus Houtt.].Molecular formula: C
15h
24o
9, molecular weight: 348.35.
Find according to the study, friedelan 3 βol, astragalus polysaccharides component A1, the compound recipe of resveratrol and Herba Leonuri glycosides A composition can effectively suppress serum total cholesterol, content of triglyceride raises and serum High Density Lipoprotein Cholesterol content reduces, and has the effect that prevention fatty liver forms.
The present invention is by rats'liver assessment of indices is found, Models of Fatty Liver rats'liver index obviously raises, and pharmaceutical composition provided by the invention can effectively prevent the liver index of Induced by High Fat Diet in Rats to raise.
The present invention is by measuring and find blood lipids index, and Models of Fatty Liver rat blood serum TG and TC value significantly raise, HDL-C value significantly reduces, and pharmaceutical composition provided by the invention can effectively prevent Induced by High Fat Diet in Rats blood lipids index to change.
The present invention is by measuring discovery to Serum ALT, AST, and Models of Fatty Liver rat blood serum ALT, AST significantly raise, and pharmaceutical composition provided by the invention can effectively prevent the rising of rat blood serum ALT, AST.
The present invention is by measuring discovery to SOD in serum, MDA, and Models of Fatty Liver rat blood serum SOD obviously reduces, MDA obviously raises, and pharmaceutical composition provided by the invention can effectively prevent the variation of rat blood serum SOD, MDA.
The present invention is by om observation is found, there is significant quantities of fat granule in Models of Fatty Liver rat hepatocytes gap, and hepatocyte is atrophing state, and pharmaceutical composition provided by the invention can effectively prevent morphological change under rat liver light microscopic.
The present invention is by electron microscopic observation is found, Models of Fatty Liver rat hepatocytes nuclear membrane fold, has obvious dense granule, smooth endoplasmic reticulum expansion, and pharmaceutical composition provided by the invention can effectively prevent morphological change under rat Electronic Speculum.
The present invention have can effectively prevent fatty liver and therapeutic effect obvious, the stable advantage that is suitable for patient's long-term taking of Quality Control.
Accompanying drawing explanation
Fig. 1 is that pharmaceutical composition of the present invention is on the morphologic impact of rat hepatocytes (400 ×) schematic diagram.
Fig. 2 is that pharmaceutical composition of the present invention is on the morphologic impact of Models of Fatty Liver rat hepatocytes (8000 ×) schematic diagram.
The specific embodiment
The present invention is pharmaceutical composition and the application thereof of prevention fatty liver, now in conjunction with specific embodiments the present invention is further described.Concrete embodiment is as follows:
Embodiment mono-
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 1 part of friedelan 3 βol, astragalus polysaccharides component A13 part, 5 parts of resveratrols and Herba Leonuri glycosides A1 part.
Embodiment bis-
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 50.5 parts of friedelan 3 βols, astragalus polysaccharides component A151.5 part, 52.5 parts of resveratrols and Herba Leonuri glycosides A50.5 part.
Embodiment tri-
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 80 parts of friedelan 3 βols, astragalus polysaccharides component A180 part, 80 parts of resveratrols and Herba Leonuri glycosides A80 part.
Embodiment tetra-
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 40.5 parts of friedelan 3 βols, astragalus polysaccharides component A141.5 part, 42.5 parts of resveratrols and Herba Leonuri glycosides A40.5 part.
Embodiment five
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 50 parts of friedelan 3 βols, astragalus polysaccharides component A150 part, 50 parts of resveratrols and Herba Leonuri glycosides A50 part.
Embodiment six
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 25.5 parts of friedelan 3 βols, astragalus polysaccharides component A126.5 part, 27.5 parts of resveratrols and Herba Leonuri glycosides A25.5 part.
Embodiment seven
Prevent a pharmaceutical composition for fatty liver, it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 100 parts of friedelan 3 βols, astragalus polysaccharides component A1100 part, 100 parts of resveratrols and Herba Leonuri glycosides A100 part.
Above-described embodiment is only for example of the present invention is clearly described, and the not restriction to embodiment.For the common technique personnel in affiliated field, can also make other changes in different forms on the basis of the above description.Here exhaustive without also giving all embodiments, and the apparent variation of being amplified out thus or variation are still among the protection domain in the invention claim.
The present invention can pass through friedelan 3 βol, astragalus polysaccharides component A1, and resveratrol and Herba Leonuri glycosides A are prepared into various multi-form medicaments, as: aqueous solvent, the forms such as powder and mixture; When preparing aqueous solvent, needs take medicine according to following weight, friedelan 3 βol 100mg, astragalus polysaccharides component A1300mg, and resveratrol 500mg and Herba Leonuri glycosides A500mg, mix, be dissolved in tri-distilled water, subpackage.
When preparing powder, needs take medicine according to following weight, friedelan 3 βol 1g, astragalus polysaccharides component A13g, resveratrol 5g and Herba Leonuri glycosides A5g, mixing, subpackage.When preparing mixture, needs take medicine according to following deal, friedelan 3 βol 1g, astragalus polysaccharides component A13g, resveratrol 5g and Herba Leonuri glycosides A5g, mixing, subpackage, fill capsule.
Experimental example
Detecting the present invention changes rats'liver index, Serum Indexes and hepatocyte electron microscopic morphology.
1, medicine: friedelan 3 βol, astragalus polysaccharides component A1, resveratrol, Herba Leonuri glycosides A said medicine all from Shanghai Ke Xing commerce and trade company limited purchase, compound methionine choline sheet purchases from Chinese Tonghua Dongbao Pharmaceutical Co., Ltd.
2, animal: Sprague-Dawley (SD) rat, 6 week age, male, 180～220g, clean level are provided by Henan Province's Experimental Animal Center.
3, experiment grouping: rat adapts to raise 1 week at laboratory, at activity, feed, feces, all without abnormal, 48 rats are divided at random 6 groups by table of random number and carry out gavage: (1) blank group; (2) Models of Fatty Liver matched group; (3) compound methionine choline group (gavage concentration: 100mg/kg); (4) pharmaceutical composition low dose group (gavage concentration: 10mg/kg); (5) dosage group (gavage concentration: 20mg/kg) in pharmaceutical composition; (6) pharmaceutical composition high dose group (gavage concentration: 30mg/kg).
4, experiment content: rats'liver index, Serum Indexes and hepatocyte electron microscopic morphology.
5, statistical method: all data are with mean ± standard deviation
represent.Group difference is relatively used ANOVA and Newman-Student multiple comparisons; T check analysis, is completed by SPSS13.0 statistical software, and bilateral P<0.05 thinks that difference has significance.
6, result
The impact of 6.1 the present invention on rats'liver index: result of the test shows, the tarnish of Models of Fatty Liver group rat fur, movable minimizing, all the other groups are without obvious adverse reaction.Blank group, Models of Fatty Liver group and each pharmaceutical composition group rat average body quality all increase with feeding time lengthening, but each group difference not statistically significant.Models of Fatty Liver group rats'liver index is significantly higher than blank group (P < 0.01), and the basic, normal, high dosage group of pharmaceutical composition rats'liver index is all significantly lower than model group (P < 0.01).(the results are shown in Table 1)
The impact of table 1 the present invention on rats'liver index
Note: with the comparison of blank group, * P<0.01; With model group comparison, #P<0.01.
The impact of 6.2 the present invention on rat blood serum TG, TC, HDL-C content: result of the test shows, Models of Fatty Liver group serum TG and TC value are significantly higher than blank group (P<0.01), and HDL-C is significantly lower than blank group (P<0.01); With the comparison of Models of Fatty Liver group, in pharmaceutical composition low dose group, pharmaceutical composition, dosage group, pharmaceutical composition high dose group rat blood serum TG, TC content obviously reduce (P<0.01), HDL-C content significantly raise (P<0.01).(the results are shown in Table 2)
The impact of table 2 the present invention on rat blood serum TG, TC, HDL-C content
Note: with the comparison of blank group, * P<0.01; With model group comparison, #P<0.01.
The impact of 6.3 the present invention on rat blood serum ALT, AST: Models of Fatty Liver group rat blood serum ALT, AST value are significantly higher than blank group (P<0.01); In pharmaceutical composition low dose group, pharmaceutical composition, dosage group, pharmaceutical composition high dose group Serum ALT, AST value are all lower than Models of Fatty Liver group (P<0.01).(the results are shown in Table 3)
The impact of table 3 the present invention on rat blood serum ALT and AST content
Note: with the comparison of blank group, * P<0.01; With model group comparison, #P<0.01.
The impact of the content of 6.4 the present invention on rat blood serum SOD and MDA: Models of Fatty Liver group SOD in serum value is significantly lower than blank group (P<0.01), and MDA value is significantly higher than blank group (P<0.01); In pharmaceutical composition low dose group, pharmaceutical composition, dosage group, pharmaceutical composition high dose group rat blood serum SOD value are higher than Models of Fatty Liver group (P<0.01), and MDA value is significantly lower than blank group (P<0.01).(the results are shown in Table 4)
The impact of the content of table 4 the present invention on rat blood serum SOD and MDA
Note: with the comparison of blank group, * P<0.01; With model group comparison, #P<0.01.
6.5 as shown in Figure 1, and the present invention is on the morphologic impact of rat hepatocytes (400 ×).As we can see from the figure, there is significant quantities of fat granule in Models of Fatty Liver rat hepatocytes gap, and hepatocyte is atrophing state.The present invention can obviously suppress morphological change under rat liver light microscopic.Blank group shown in Fig. 1 is A; Models of Fatty Liver group is B; Compound methionine choline group is C; Pharmaceutical composition dosage group is D; In pharmaceutical composition, dosage group is E; Pharmaceutical composition high dose group is F.
6.6 as shown in Figure 2, and the present invention is on the morphologic impact of rat hepatocytes (Electronic Speculum 8000 ×).As can be seen from the figure, Models of Fatty Liver rat hepatocytes nuclear membrane fold, has obvious dense granule, smooth endoplasmic reticulum expansion.The present invention can obviously suppress morphological change under rat Electronic Speculum.Blank group shown in Fig. 2 is A; Models of Fatty Liver group is B; Compound methionine choline group is C; Pharmaceutical composition low dose group is D; In pharmaceutical composition, dosage group is E; Pharmaceutical composition high dose group is F.
The form of the pharmaceutically acceptable carrier described in the present invention or diluent and feature are by the amount of the active component mixing with it, route of administration, physiological disposition (comprising absorption, distribution, metabolism, excretion) and other known variable are determined.These carriers must be " acceptable ", and they should can be adaptive with other composition of preparation, can not affect the effect of said preparation and can not be harmful to the receiver of said preparation.For example, the pharmaceutical carriers of using can be solid or liquid.The example of solid carrier is lactose, hargil, sucrose, Pulvis Talci, gelatin, agar, pectin, Radix Acaciae senegalis, magnesium stearate, stearic acid, Polyethylene Glycol, polyvinylpyrrolidone, collagen hydrolysate etc.The example of liquid-carrier is phosphate buffered saline(PBS), syrup, emulsion, wetting agent, sterile solution etc.Similarly, carrier or diluent can comprise the time lagged type material that this area is known, as independent glyceryl monostearate or distearin or with the mixture of wax.Can use large-scale medicament forms.Therefore,, if use solid carrier, said preparation can become tablet, with powder or particle form, be placed on the form of hard gelatine capsule, one-tenth lozenge or lozenge.The variation of the amount of solid carrier will be very large, but the better 50mg that is about is to about 1g.When using during liquid-carrier, preparation can become the form of syrup, emulsion, soft gelatine capsule.
Claims (6)
1. a pharmaceutical composition that prevents fatty liver, is characterized in that: it is formulated that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol, astragalus polysaccharides component A1, resveratrol and Herba Leonuri glycosides A composition.
2. the pharmaceutical composition of prevention fatty liver according to claim 1, it is characterized in that: it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol 1-100 part, astragalus polysaccharides component A13-100 part, resveratrol 5-100 part and Herba Leonuri glycosides A1-100 part.
3. the pharmaceutical composition of prevention fatty liver according to claim 1, it is characterized in that: it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol 1-80 part, astragalus polysaccharides component A13-80 part, resveratrol 5-80 part and Herba Leonuri glycosides A1-80 part.
4. the pharmaceutical composition of prevention fatty liver according to claim 1, it is characterized in that: it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol 1-50 part, astragalus polysaccharides component A13-50 part, resveratrol 5-50 part and Herba Leonuri glycosides A1-50 part.
5. the pharmaceutical composition of prevention fatty liver according to claim 1, it is characterized in that: it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 1 part of friedelan 3 βol, astragalus polysaccharides component A13 part, 5 parts of resveratrols and Herba Leonuri glycosides A1 part.
6. the application of the pharmaceutical composition as described in claim 1-5 in the medicine of preparation prevention fatty liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410033079.8A CN103735564B (en) | 2014-01-21 | 2014-01-21 | The pharmaceutical composition of prevention fatty liver and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410033079.8A CN103735564B (en) | 2014-01-21 | 2014-01-21 | The pharmaceutical composition of prevention fatty liver and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735564A true CN103735564A (en) | 2014-04-23 |
| CN103735564B CN103735564B (en) | 2016-01-20 |
Family
ID=50492680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410033079.8A Expired - Fee Related CN103735564B (en) | 2014-01-21 | 2014-01-21 | The pharmaceutical composition of prevention fatty liver and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735564B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977889B (en) * | 2005-12-05 | 2012-03-21 | 山东轩竹医药科技有限公司 | Medicinal composition of astragalus, salvia miltrorrhiza and oxymatrine, and its preparing method |
-
2014
- 2014-01-21 CN CN201410033079.8A patent/CN103735564B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977889B (en) * | 2005-12-05 | 2012-03-21 | 山东轩竹医药科技有限公司 | Medicinal composition of astragalus, salvia miltrorrhiza and oxymatrine, and its preparing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735564B (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110169992B (en) | Composition for improving intrahepatic cholestasis and preparation method thereof | |
| CN103479635A (en) | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof | |
| CN110585262B (en) | Traditional Chinese medicine composition for treating and/or preventing liver and gall diseases and application thereof | |
| CN102526423A (en) | Medicine composition for treating ischemic heart disease | |
| CN103735564B (en) | The pharmaceutical composition of prevention fatty liver and application thereof | |
| CN103735563B (en) | The pharmaceutical composition for the treatment of fatty liver and application thereof | |
| CN105878221A (en) | Pharmaceutical composition for preventing atherosclerosis and application thereof | |
| CN103751206B (en) | The pharmaceutical composition of prevention Alzheimer formula syndrome and application thereof | |
| CN103751207B (en) | The pharmaceutical composition for the treatment of Alzheimer formula syndrome and application thereof | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN103341117B (en) | Composition for treating hepatitis B and preparation method and usage thereof | |
| CN103735565B (en) | The pharmaceutical composition of prevention essential hypertension and application thereof | |
| CN105327115A (en) | Phellinus linteus catharsis formula for prevention and cure of type II diabetes and preparation process thereof | |
| CN106344885B (en) | Pharmaceutical composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN105147709A (en) | Novel application of tenofovir disoproxil fumarate or medicinal salt thereof | |
| CN104288579A (en) | Traditional Chinese medicine for treating chronic nephritis and preparation method thereof | |
| CN103751205B (en) | The pharmaceutical composition for the treatment of vascular dementia and application thereof | |
| CN103751203B (en) | The pharmaceutical composition for the treatment of essential hypertension and application thereof | |
| CN105497003B (en) | Application of the epimedium aglucone in preparation prevention or treatment pulmonary fibrosis medicine | |
| CN106420901B (en) | A kind of herbal mixture for treating fatty liver | |
| CN114159516B (en) | Traditional Chinese medicine composition for preventing and treating hashimoto thyroiditis and application thereof | |
| CN103721176B (en) | Chinese medicine preparation for the treatment of breast cancer relapse transfer and preparation method thereof | |
| CN104147017B (en) | Medicinal composition for treating liver cirrhosis and application thereof | |
| CN106265913A (en) | A kind of pharmaceutical composition containing monoammonium glycyrrhizinate and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20170121 |